The 17th CPHI & PMEC India, orchestrated by Informa Markets, a prominent name in organizing B2B events in India, began with insightful dialogues on crucial topics and exclusive sessions with prominent industry figures aiming to address transformative industry trends and hurdles.
Commencing on November 26 at the India Expo Centre, Greater Noida, Delhi-NCR, the event spotlights the burgeoning potential of India’s pharmaceutical sector. The inaugural day featured the Pharma Connect Congress delving into critical themes that influence the pharmaceutical landscape, alongside the Pharma Leaders Roundtable, a private platform for senior executives to discuss transformative market trends and challenges.
AVPS Chakravarthy, WPO’s Global Ambassador, shared, “India’s pharmaceutical innovations, like Carticel cancer therapy and the macrolide antibiotic Nafithromycin, underscore the dual priorities of cost-effectiveness and efficacy, reinforcing India as the ‘world’s pharmacy’.”
He added, “Events such as CPHI & PMEC India are essential for fostering collaboration and innovation in AI-driven drug quality checks, eco-friendly packaging, and startup innovations, propelling the industry towards higher value creation and leadership in both market size and quality.”
Dr. Veeramani, Pharmexcil’s chairman, remarked on India’s dominance in pharmaceutical solutions to over 200 countries and its role in APIs, completed dosages, clinical research, and pharmacovigilance. According to him, platforms like CPHI portray India’s trajectory from $55 billion to aspirational growth goals of $130 billion by 2030 and $450 billion by 2047.
K Raja Bhanu, Pharmexcil’s director-general, highlighted export growth, currently at $55 billion with $27.85 billion from exports, projecting further growth to $130 billion by 2030 and $450 billion by 2047. Key areas include manufacturing, analytics, AI, and machine learning.
Namit Joshi, Pharmexcil’s vice-chairman, praised India’s evolution as a global pharmaceutical force—the ‘Pharmacy of the World’—with significant contributions to COVID-19 vaccine distribution and innovations like nanoparticles and enhanced drug delivery systems.
Harish K Jain, FOPE’s president, emphasized the industry’s current valuation of $60 billion and projected export advancements by 2030. Integrating advancements in AI, machine learning, and biologics positions India for future pharmaceutical dominance.
Informa Markets India’s MD, Yogesh Mudras, emphasized the nation’s manufacturing prowess, ranking 3rd globally by volume and 14th by value, contributing significantly to the GDP. The sector benefits from low-cost manufacturing and R&D, supported by a skilled workforce.
The event bolsters India’s competitive edge in global healthcare, showcasing emerging disruptors paving a futuristic path for the industry.
Adam Anderson of Informa Markets B.V noted the expanding biopharmaceutical sector, poised to represent a significant global market share by 2027, positioning India as a key leader.
The event features over 2,000 exhibitors and 50,000 attendees from 150+ countries, covering diverse areas like machinery, packaging, analytics, and more to promote strategic partnerships.
Exhibitors include acclaimed names such as Dr. Reddy’s Laboratories, Biocon, Glenmark Lifesciences, and others, alongside PMEC exhibitors like ACG and Accupack Engineering, unveiling cutting-edge equipment innovations.
The event garners support from pivotal industry associations, cementing its standing in the global pharmaceutical space.
The Pharma Connect Congress encouraged dialogues on continual innovation and flexible manufacturing for future therapeutics.
Day 2 promises insightful sessions focusing on sustainability, leadership, and women’s roles in pharma, offering a platform for addressing eco-conscious challenges, enhancing talent diversity, and empowering women in the industry.